M&A, CGT and Disruptive Drugs Focus for CSL Going Forward

Excerpt

Over the past year, CSL has unveiled some big deals that will change the breadth of its focus in a major way.

Article Summary

The company recently closed an $18.8 billion deal to buy Swiss pharmaceuticals firm Vifor, which makes products for iron deficiency and kidney disease. This was a huge acquisition, and one that creates a new division within the company – CSL Vifor. Vifor is expected to add between $US300 million and $330 million to CSL’s profits next year.

This month, the company again surprised the market with a $US200 million licensing deal with US biotech Arcturus that will give CSL access to a range of next-generation mRNA vaccines Arcturus is developing.

It’s hoped these shots will require lower doses and can be stored at more reasonable temperatures than the mRNA COVID vaccines on the market. The deal also shows that CSL is not walking away from the mRNA space, which looks set to heat up once COVID vaccine maker Moderna sets up shop in Victoria.

This month CSL held its research and development briefing, where its experts run through its progress in bringing new drugs to market.

This annual presentation is watched closely by market analysts because it outlines a timeline for when disruptive drugs might be ready for commercial launch and the market opportunities.

The presentation revealed updates to a few key products that could disrupt the standard of care across a range of industries.

This month CSL held its research and development briefing, where its experts run through its progress in bringing new drugs to market.

This annual presentation is watched closely by market analysts because it outlines a timeline for when disruptive drugs might be ready for commercial launch and the market opportunities.

The presentation revealed updates to a few key products that could disrupt the standard of care across a range of industries.

 

 About CSL Behring.

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment, and to prevent hemolytic diseases in newborns.

 

[Source: Here’s what our $132b biotech giant plans to do next (smh.com.au)]

 

Comments

Leave A Comment

Leave a Reply

Your email address will not be published.

bag